Toddlers Bone MetabolismNCT04799028
Evaluation of Toddler Milk Containing L.Reuteri, Galacto-oligosaccharides and Palm-Oil Free Fat Blend
A study testing Traditional cow's milk, Experimental milk and Habitual diet in people with Toddlers Bone Metabolism, run by Société des Produits Nestlé (SPN) at 1 site in Philippines.
Trial summary
The purpose of this study is to evaluate the effects of experimental growing up milk (EXPL) as compared to traditional children's fortified milk (CTRL) fed for 6 months on bone mass index. Read more about this study
- Who is it for?
- Ages 2 to 3 yearsHealthy volunteers can take part
- Conditions the study is for
- Toddlers Bone Metabolism
- What is being tested?
- Traditional cow's milk, Experimental milk and Habitual diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 273 participants
- Where
- 1 sitePhilippines
- Study dates
- 19 Jun 2021to 28 Oct 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 3 years
- All sexes
- Healthy volunteers accepted
- Child
All subjects must comply with all the following criteria:
- Written informed consent has been obtained from the parent(s)/legally acceptable representative (LAR).
- Singleton, full-term gestational birth (≥ 37 completed weeks of gestation), with a birth weight of ≥ 2.5 kg and ≤ 4.5 kg.
- Child is between 24 months ±1 week to 36 months ±1 week.
- Child is not currently consuming nor has consumed any formulas or taking any supplements with pre- or probiotics at enrolment or in the past month.
- Child's parent(s)/guardian is of legal age of consent, must understand the informed consent and other study documents, and is willing and able to fulfill the requirements of the study protocol.
All subjects presenting one or more of the following criteria are excluded from participation in the study:
- Chronic infectious, metabolic, genetic illness or other disease including any condition that impacts feeding or growth.
- History of bone, malabsorption, metabolic, congenital or chromosomal abnormality known to affect feeding or growth.
- Use of systemic antibiotics or anti-mycotic medication in the 4 weeks preceding enrollment.
- Known or suspected cows' milk protein intolerance / allergy, or lactose intolerance, or severe food allergies that impact diet.
- Current breast milk feeding in place of all other milk, and/or milk alternatives.
- Clinical signs of severe micronutrient deficiencies.
- Parents not willing / not able to comply with the requirements of study protocol.
- Child's participation in another interventional clinical trial.
Trial locations and contacts
1 site in 1 country.
Philippines1 site
Asian Foundation for Tropical Medicine, Inc.
City of Muntinlupa, 1781
About this study
Official title: Evaluation of Toddler Milk Containing L.Reuteri, Galacto-oligosaccharides and Palm-Oil Free Fat Blend On Bone Metabolism Among Healthy Toddlers
The purpose of this study is to evaluate the effects of experimental growing up milk (EXPL) as compared to traditional children's fortified milk (CTRL) fed for 6 months on bone mass index.
Read the detailed description
A randomized, double-blind controlled clinical trial was chosen to study the effects of toddler milk containing L. reuteri and GOS (4g/L) and a low sn-1, -3 fat blend when compared to a control formula. There is an additional unblinded habitual intake reference group (REF) for "real-world" comparison (including 58% non-dairy drinkers according to observational data).
- Conditions
- Toddlers Bone Metabolism
- Being tested
- Traditional cow's milk, Experimental milk, Habitual diet
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Traditional cow's milkOther
Fortified cow's milk
Experimental milkOther
Milk with synbiotics and fat blend
Habitual dietOther
Habitual diet
| Study group | Role | What they receive |
|---|---|---|
| Traditional children's fortified cow's milk | Active comparator | Not described Receives: Other: Traditional cow's milk |
| New toddler milk with synbiotics and fat blend | Experimental | Not described Receives: Other: Experimental milk |
| Toddlers consuming habitual diet | Other | Not described Receives: Other: Habitual diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Speed of sound (SOS)
Speed of sound (SOS) using a quantitative ultrasound methods measured by Pediatric Sunlight 9000 device
Measured: Day 1, Day 90, Day 180
Secondary outcomes (21)
GI tolerance and stooling patterns
Stool patterns including stool frequency will be recorded retrospectively via 24-hour GI Symptom and Behavior Recall
Measured: Day 1
GI tolerance and stooling patterns
Stool patterns including stool consistency will be recorded retrospectively via 24-hour GI Symptom and Behavior Recall
Measured: Day 1
GI tolerance and stooling patterns
Stool patterns including stool frequency will be recorded using 3-day GI Symptom and Behavior diary
Measured: Day 90, Day 180
GI tolerance and stooling patterns
Stool patterns including stool consistency will be recorded using 3-day GI Symptom and Behavior diary
Measured: Day 90, Day 180
GI tolerance and stooling patterns
Parent perceptions of GI symptoms using parent-reported questionnaire Toddler Gut Comfort Questionnaire (GCQ) using VAS from 1-Never to 6-Always with higher scores indicating increasing GI burden.
Measured: Day 1, Day 90, Day 180
GI tolerance and stooling patterns
Parent perceptions of GI-related behaviors using parent-reported questionnaire Toddler Gut Comfort Questionnaire (GCQ) using VAS from 1-Never to 6-Always with higher scores indicating increasing GI burden.
Measured: Day 1, Day 90, Day 180
Stool analyses
Excretion of fecal calcium fatty acid soaps
Measured: Day 1, Day 180
Stool analyses
Measurement of stool calcium content
Measured: Day 1, Day 180
Serum vitamin D
Measured by serum 25[OH]D concentration requiring 1mL of whole blood sample.
Measured: Day 1, Day 180
Urine and Blood bone turnover markers
Bone accretion markers in urinary [C-terminal cross-linked telopeptides of type I collagen (CTX)
Measured: Day 1, Day 180 (EXPL and CTRL groups only)
Urine and Blood bone turnover markers
serum procollagen type I N-terminal propeptide (PINP)
Measured: Day 1, Day 180 (EXPL and CTRL groups only
Gut microbiota
Gut microbiota analyzed for microbiome composition and diversity using next generation shotgun metagenomics sequencing, requiring 3g of stool sample.
Measured: Day 1, Day 180
Stool analyses
Determination of fecal short chain fatty acids (SCFAs)
Measured: Day 1, Day 180
Stool analyses
Fecal pH and metabolism.
Measured: Day 1, Day 180
Stool analyses
Fecal markers of gut health
Measured: Day 1, Day 180
Physical strength
Hand grip test (Jamar hand dynamometer) tailored for toddlers will be used as previously described Bohannon et al Pediatric Physical Therapy 2017.
Measured: Day 1, Day 180
Vitamin B
serum vitamin B concentration requiring 2 mL of whole blood sample.
Measured: Day 1, Day 180
Dietary intake patterns
Intake patterns are assessed using parent-reported questionnaire Child Eating Behavior Questionnaire including variety of food groups consumed as well as behaviors rated from Never to Always.
Measured: Day 1, Day 180
Child quality of life using validated ITQOL SF-47 questionnaire
assessed using the parent-reported questionnaires
Measured: Day 1, Day 180
Outdoor Playtime
Assessed using parent-reported questionnaire on Outdoor Playtime recording number of hours child spent outside.
Measured: Day 1 and Day 180
Child temperament
Children's Behavior Questionnaire (very short form), consisting of 36 questions and 3 scales on child temperament domains Surgency, Negative Affect and Effort Control with each question ranging 1-extremely untrue to 7- extremely true of parent observing various behaviors.
Measured: Day 1, Day 180
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2021
- Study start19 Jun 2021
- Primary completion16 Aug 2022
- Study completion28 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Toddlers Bone MetabolismStudies of the same condition, open and under way.
- More trials run by Société des Produits Nestlé (SPN)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 273 participants (actual)
Sponsor and investigators
- Lead sponsor
- Société des Produits Nestlé (SPN)
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04799028
- Sponsor's protocol ID
- 20.10.INF
- Status last verified
- Mar 2023
- First submitted
- 11 Mar 2021
- Last updated
- 24 Mar 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Bonnet N, Capeding MR, Siegwald L, Garcia-Garcera M, Desgeorges T, Tytgat HLP, Krattinger LF, Lebumfacil J, Phee LC, Moll JM, Gudjonsson A, Rodriguez-Garcia P, Baruchet M, Feige JN, Jankovic I, Chen Y, Egli D, Horcajada MN. A young child formula with Limosilactobacillus reuteri and GOS modulates gut microbiome and enhances bone and muscle development: a randomized trial. Nat Commun. 2025 Dec 12;17(1):237. doi: 10.1038/s41467-025-66930-2.
PubMed 41387706
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Toddler Milk Containing L.Reuteri, Galacto-oligosaccharides and Palm-Oil Free Fat Blend On Bone Metabolism Among Healthy Toddlers
- ClinicalTrials.gov ID
- NCT04799028
- Acronym / sponsor ID
- 20.10.INF
- Conditions
- Toddlers Bone Metabolism
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 273 participants (actual)
- Lead sponsor
- Société des Produits Nestlé (SPN)Industry (pharma, biotech, devices)
- Study start
- 19 Jun 2021 (actual)
- Primary completion
- 16 Aug 2022 (actual)
- Study completion
- 28 Oct 2022 (actual)
- First posted
- 16 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effects of experimental growing up milk (EXPL) as compared to traditional children's fortified milk (CTRL) fed for 6 months on bone mass index.
Detailed description
A randomized, double-blind controlled clinical trial was chosen to study the effects of toddler milk containing L. reuteri and GOS (4g/L) and a low sn-1, -3 fat blend when compared to a control formula. There is an additional unblinded habitual intake reference group (REF) for "real-world" comparison (including 58% non-dairy drinkers according to observational data).
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Traditional children's fortified cow's milk | Active comparator | Other: Traditional cow's milk |
| New toddler milk with synbiotics and fat blend | Experimental | Other: Experimental milk |
| Toddlers consuming habitual diet | Other | Other: Habitual diet |
Who may qualify
- Ages
- 2 to 3 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Traditional cow's milkFortified cow's milk | Other | Traditional children's fortified cow's milk |
| Experimental milkMilk with synbiotics and fat blend | Other | New toddler milk with synbiotics and fat blend |
| Habitual dietHabitual diet | Other | Toddlers consuming habitual diet |
Primary outcome
Speed of sound (SOS)
Time frame: Day 1, Day 90, Day 180
Speed of sound (SOS) using a quantitative ultrasound methods measured by Pediatric Sunlight 9000 device
21 secondary outcomes
GI tolerance and stooling patterns
Time frame: Day 1
GI tolerance and stooling patterns
Time frame: Day 1
GI tolerance and stooling patterns
Time frame: Day 90, Day 180
GI tolerance and stooling patterns
Time frame: Day 90, Day 180
GI tolerance and stooling patterns
Time frame: Day 1, Day 90, Day 180
GI tolerance and stooling patterns
Time frame: Day 1, Day 90, Day 180
Stool analyses
Time frame: Day 1, Day 180
Stool analyses
Time frame: Day 1, Day 180
Serum vitamin D
Time frame: Day 1, Day 180
Urine and Blood bone turnover markers
Time frame: Day 1, Day 180 (EXPL and CTRL groups only)
Urine and Blood bone turnover markers
Time frame: Day 1, Day 180 (EXPL and CTRL groups only
Gut microbiota
Time frame: Day 1, Day 180
Stool analyses
Time frame: Day 1, Day 180
Stool analyses
Time frame: Day 1, Day 180
Stool analyses
Time frame: Day 1, Day 180
Physical strength
Time frame: Day 1, Day 180
Vitamin B
Time frame: Day 1, Day 180
Dietary intake patterns
Time frame: Day 1, Day 180
Child quality of life using validated ITQOL SF-47 questionnaire
Time frame: Day 1, Day 180
Outdoor Playtime
Time frame: Day 1 and Day 180
Child temperament
Time frame: Day 1, Day 180
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2023.
- Derived from this study: PubMed 41387706Bonnet N, Capeding MR, Siegwald L, Garcia-Garcera M, Desgeorges T, Tytgat HLP, Krattinger LF, Lebumfacil J, Phee LC, Moll JM, Gudjonsson A, Rodriguez-Garcia P, Baruchet M, Feige JN, Jankovic I, Chen Y, Egli D, Horcajada MN. A young child formula with Limosilactobacillus reuteri and GOS modulates gut microbiome and enhances bone and muscle development: a randomized trial. Nat Commun. 2025 Dec 12;17(1):237. doi: 10.1038/s41467-025-66930-2.
- Individual participant dataSharing planned: Undecided
Related trials for Toddlers Bone Metabolism
RecruitingPhase 2
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Achondroplasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Traditional cow's milk, Experimental milk and Habitual diet in people with Toddlers Bone Metabolism, run by Société des Produits Nestlé (SPN) at 1 site in Philippines.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Philippines. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Speed of sound (SOS) (time frame: Day 1, Day 90, Day 180). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04799028, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2023.